

### Amendments to the Claims

**1. (Original)** A quickly disintegrating solid preparation comprising a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30 µm to 300 µm, c) a disintegrating agent, and d) a cellulose compound.

**2. (Original)** The preparation according to claim 1, which is an intraorally quickly disintegrating solid preparation.

**3. (Original)** The preparation according to claim 1, which is a tablet preparation.

**4. (Original)** The preparation according to claim 1, which contains 40 to 95 parts of a saccharide or sugar alcohol per 100 parts of the solid preparation by weight.

**5. (Original)** The preparation according to claim 1, which contains 0.5 to 15 parts of a disintegrating agent per 100 parts of the solid preparation by weight.

**6. (Original)** The preparation according to claim 1, which contains 0.5 to 40 parts of a cellulose compound per 100 parts of the solid preparation by weight.

**7. (Original)** The preparation according to claim 1, wherein the saccharide is one or more saccharides selected from the group consisting of glucose, fructose, lactose, sucrose, and trehalose.

**8. (Original)** The preparation according to claim 1, wherein the saccharide is lactose.

**9. (Original)** The preparation according to claim 1, wherein the sugar alcohol is one or more sugar alcohols selected from the group consisting of D-mannitol, erythritol, xylitol, maltitol, and sorbitol.

**10. (Original)** The preparation according to claim 1, wherein the sugar alcohol is D-mannitol.

**11. (Original)** The preparation according to claim 1, characterized in that D-mannitol with the mean particle diameter of 30 µm to 300 µm is used as the saccharide or sugar alcohol with the mean particle diameter of 30 µm to 300 µm.

**12. (Original)** The preparation according to claim 1, wherein the disintegrating agent is one or more disintegrating agents selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium, and crospovidone.

**13. (Original)** The preparation according to claim 1, wherein the cellulose compound is one or more cellulose compounds selected from the group consisting of crystalline cellulose, powder cellulose, low substituted hydroxypropylcellulose, and carmellose.

**14. (Original)** The preparation according to claim 1, wherein the active ingredient is manidipine hydrochloride.

**15. (Original)** The preparation according to claim 1, wherein the active ingredient is voglibose.

**16. (Original)** The preparation according to claim 1, wherein the active ingredient is candesartan cilexetil.

**17. (Original)** The preparation according to claim 1, wherein the active ingredient is pioglitazone hydrochloride.

**18. (Original)** The procedure for production of the preparation according to claim 1, characterized in that a mixture containing a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30 µm to 300 µm, c) a disintegrating agent, and d) a cellulose compound is subjected to compression molding.

**19-32. (Cancelled)**